Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.

ABSTRACT:

Background

Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition of TNF-α inhibitors such as infliximab (IFX) may expedite symptom resolution and shorten CS duration. Thus, we conducted the first retrospective study, to our knowledge, evaluating symptom resolution in patients with irEC treated with and without IFX.

Methods

Data were collected from the medical records of patients diagnosed with irEC. The primary endpoint was time to symptom resolution for irEC for cases managed with IFX plus CS (IFX group) versus CS alone (CS group). Duration of

SUBMITTER: Johnson DH 

PROVIDER: S-EPMC6180568 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature